CYDY - CytoDyn Won't Make Your Dreams Come True

• Leronlimab is a unique molecule targeting a unique pathway, which gives it strength in numerous indications.
• The company's press doesn't correlate with its value according to the market or other pharmaceutical companies.
• The company's annoying ability of refusing to admit mistakes and manipulating data makes it tough to place a fair value.
• We recommend the company's messaging becomes much clearer and more informative.
• Leronlimab, subject to approval, does have the ability to drive significant shareholder rewards.

For further details see: